Do you want to read an article? Please log in or register.
Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial
Thrombosis and Stroke
COMMENTED
Related content
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials
Eur Heart J.
Koskinas KC, Siontis GCM, Piccolo R, Mavridis D, Räber L, Mach F, Windecker S
doi: 10.1093/eurheartj/ehx566.
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
Comparison of Recommended Eligibility for Primary Prevention Statin Therapy Based on the US Preventive Services Task Force Recommendations vs the ACC/AHA Guidelines
JAMA.
Pagidipati NJ, Navar AM, Mulder H, Sniderman AD, Peterson ED, Pencina MJ
doi: 10.1001/jama.2017.3416.
COMMENTED
Lipid-Lowering Drugs
Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants
Am Heart J.
Yebyo HG, Aschmann HE, Kaufmann M, Puhan MA
doi: 10.1016/j.ahj.2018.12.007.
Cardiovascular Risk and DiseasesHeart FailureMyocardial InfarctionThrombosis and Stroke
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
Circulation.
Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Fabbrini E, Sun T, Li Q, Desai M, Matthews DR; CANVAS Program Collaborative Group
doi: 10.1161/CIRCULATIONAHA.
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
LDL-Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men with Primary Elevations of LDL-Cholesterol Levels of 190 mg/dL or Above: Analyses from the WOSCOPS 5-year Randomised Trial and 20-year Observational Follow-Up
Circulation.
Vallejo-Vaz AJ, Robertson M, Catapano AL, Watts GF, Kastelein JJ, Packard CJ, Ford I, Ray KK
doi: 10.1161/
Atrial FibrillationThrombosis and Stroke
Patent foramen ovale closure vs. medical therapy for cryptogenic stroke: a meta-analysis of randomized controlled trials
Eur Heart J.
Ahmad Y, Howard JP, Arnold A, Shin MS, Cook C, Petraco R, Demir O, Williams L, Iglesias JF, Sutaria N, Malik I, Davies J, Mayet J, Francis D, Sen S
doi: 10.1093/eurheartj/ehy121.
RECOMMENDED
Heart, Artery and Coronary DiseasesLipid-Lowering Drugs
Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
JAMA Cardiol.
Deedwania P, Murphy SA, Scheen A, Badariene J, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TR, Sabatine MS, Giugliano RP
doi: 10.1001/jamacardio.2020.3151.
RECOMMENDED
Cardiovascular Risk and DiseasesHeart, Artery and Coronary Diseases
Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
J Am Heart Assoc
Ambrosy AP, Yang J, Sung SH, Allen AR, Fitzpatrick JK, Rana JS, Wagner J, Philip S, Abrahamson D, Granowitz C, Go AS
doi: 10.1161/JAHA.120.020377
Lipid-Lowering Drugs
A Long-term Benefit Approach vs Standard Risk-Based Approaches for Statin Eligibility in Primary Prevention
JAMA Cardiol.
Thanassoulis G, Sniderman AD, Pencina MJ
doi: 10.1001/jamacardio.